# JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure

Source: https://onco.cc/trials/nct07175389/  
OnCo record `nct07175389` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of serplulimab in pancreatic cancer, run by West China Hospital, not yet recruiting.

## Summary

JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure is a phase 1/2, interventional study registered as NCT07175389 by West China Hospital, with a registry enrolment figure of 10 participants, started 2026-09-01 and due to reach its primary completion in 2028-09-01. Interventions recorded: JDB153; Serplulimab. Conditions listed: Refractory Pancreatic Ductal Adenocarcinoma; Refractory Pancreatic Adenocarcinoma. Primary outcome: Incidence of Treatment-Related Adverse Events; Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: "* 1\) Histologically or cytologically confirmed diagnosis of locally advanced, unresectable, or metastatic pancreatic cancer; 2) Age 18-75 years, inclusive; no sex restrictions; 3) Life expectancy ≥12 weeks; 4) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; 5) Documented dis". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07175389
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial of JDB153 Combined With Serplulimab for the Treatment of Pancreatic Cancer Refractory to Standard Therapy
- Sponsor: West China Hospital
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT07175389: https://clinicaltrials.gov/study/NCT07175389

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Serplulimab](https://onco.cc/drugs/serplulimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07175389.json